Literature DB >> 28720207

Thrombotic Microangiopathy: A Multidisciplinary Team Approach.

Craig E Gordon1, Vipul C Chitalia1, J Mark Sloan2, David J Salant1, David L Coleman3, Karen Quillen2, Katya Ravid4, Jean M Francis5.   

Abstract

Thrombotic microangiopathy (TMA) is characterized by the presence of microangiopathic hemolytic anemia and thrombocytopenia along with organ dysfunction, and pathologically, by the presence of microthrombi in multiple microvascular beds. Delays in diagnosis and initiation of therapy are common due to the low incidence, variable presentation, and poor awareness of these diseases, underscoring the need for interdisciplinary approaches to clinical care for TMA. We describe a new approach to improve clinical management via a TMA team that originally stemmed from an Affinity Research Collaborative team focused on thrombosis and hemostasis. The TMA team consists of clinical faculty from different disciplines who together are charged with the responsibility to quickly analyze clinical presentations, guide laboratory testing, and streamline prompt institution of treatment. The TMA team also includes faculty members from a broad range of disciplines collaborating to elucidate the pathogenesis of TMA. To this end, a clinical database and biorepository have been constructed. TMA leaders educate front-line providers from other departments through presentations in various forums across multiple specialties. Facilitated by an Affinity Research Collaborative mechanism, we describe an interdisciplinary team dedicated to improving both clinical care and translational research in TMA.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Thrombotic microangiopathy (TMA); clinical care; complement-mediated hemolytic uremic syndrome (CM-HUS); hematology; multidisciplinary team; nephrology; rare disorder; thrombotic thrombocytopenic purpura (TTP); translational research

Mesh:

Year:  2017        PMID: 28720207     DOI: 10.1053/j.ajkd.2017.05.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Etiology and Outcomes of Thrombotic Microangiopathies.

Authors:  Guillaume Bayer; Florent von Tokarski; Benjamin Thoreau; Adeline Bauvois; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Louis Bernard; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Matthias Buchler; Cécile Vigneau; Fadi Fakhouri; Jean-Michel Halimi
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-12       Impact factor: 8.237

2.  Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation.

Authors:  Benjamin Thoreau; Florent von Tokarski; Adeline Bauvois; Guillaume Bayer; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Louis Bernard; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Véronique Frémeaux-Bacchi; Cécile Vigneau; Fadi Fakhouri; Jean-Michel Halimi
Journal:  Clin J Am Soc Nephrol       Date:  2021-09       Impact factor: 10.614

3.  Postsurgical Thrombotic Microangiopathy and Deregulated Complement.

Authors:  Thijs T W van Herpt; Sjoerd A M E G Timmermans; Walther N K A van Mook; Bas C T van Bussel; Iwan C C van der Horst; Jos G Maessen; Ehsan Natour; Pieter van Paassen; Samuel Heuts
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

4.  Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation.

Authors:  Priyamvada Singh; Hui Chen; Craig E Gordon; Sandeep Ghai; J Mark Sloan; Karen Quillen; Sara Moradi; Vipul Chitalia; Amitabh Gautam; Joel Henderson; Jean M Francis
Journal:  Kidney Med       Date:  2019-05-09

5.  Optimal management of atypical hemolytic uremic disease: challenges and solutions.

Authors:  Rupesh Raina; Manpreet K Grewal; Yeshwanter Radhakrishnan; Vineeth Tatineni; Meredith DeCoy; Linda Lg Burke; Arvind Bagga
Journal:  Int J Nephrol Renovasc Dis       Date:  2019-09-04

6.  Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy.

Authors:  Precil Diego Miranda de Menezes Neves; Rafael A Souza; Fábio M Torres; Fábio A Reis; Rafaela B Pinheiro; Cristiane B Dias; Luis Yu; Viktoria Woronik; Luzia S Furukawa; Lívia B Cavalcante; Stanley de Almeida Araújo; David Campos Wanderley; Denise M Malheiros; Lectícia B Jorge
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

7.  What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study.

Authors:  Jean-Michel Halimi; Benjamin Thoreau; Florent von Tokarski; Adeline Bauvois; Juliette Gueguen; Nicolas Goin; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Adrien Lemaignen; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Véronique Frémeaux-Bacchi; Cécile Vigneau; Guillaume Bayer; Fadi Fakhouri
Journal:  BMC Nephrol       Date:  2022-01-20       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.